Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in MS

Biogen Idec’s orally administered compound BG-12 has successfully completed the first of two pivotal Phase 3 clinical trials for people with relapsing-remitting multiple sclerosis (RRMS), having met the primary and all secondary study endpoints. The anti-neuroinflammatory and neuroprotective effects reported for BG-12 suggest that this FDA fast-tracked drug may also benefit ALS patients.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail